Please assess the completion status of the following clinical trial:

Trial Title: Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infant 6-11 week of age~* Infant born after 37-42 week of pregnancy~* Infant weighting more than 2.5 kg at birth~* Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form~* Parents commit themselves to comply with the indication of the investigator and with the schedule of the trial~* Mother at least graduate from elementary school~* Received Hepatitis B vaccine (Bio Farma) at birth~Exclusion Criteria:~* Child concomitantly enroll or schedule to be enroll in another trial~* Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5 Celsius on Day 0)~* Known history of allergy to any component of the vaccine component (e.g.formaldehyde)~* History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular injection~* Known history of congenital or acquired immunodeficiency (including HIV infection)~* Child who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived product or long term corticotherapy (\>2 weeks)~* Other vaccination within the 1 month prior to inclusion with the exception of BCG and poliomyelitis~* Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objective~* Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B infection

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 11 Weeks
- Healthy Volunteers: t

Study Arms:
- DTP/HB/Hib Vaccine (Batch: A) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
- DTP/HB/Hib vaccine (Batch: B) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
- DTP/HB/Hib vaccine (Batch: C) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal

Based on this trial design, predict the completion outcome and termination type (if applicable).